GPBAR1 and metabolic disease: INT-767, a semisynthetic BA that acts as a dual FXR and TGR5 (G-protein coupled receptor) agonist, has been found to be a slightly more potent activator of FXR, which also has the ability to alleviate liver injury and metabolic disorders (Baghdasaryan et al., 2011).